Moreover, the pooled analysis of the prognostic significance of EpCAM+ CTCs from patients in stage I to III (CTCs threshold for non-metastatic patients >1 per 7.5 mL blood) showed the presence of CTCs as an independent prognostic factor for inferior disease-free survival (DFS), distant DFS, breast cancer-specific survival, and OS [33]. Here, EPCAM is linked to breast carcinoma.